Renal Osteodystrophy and Aging

Seminars in Nephrology

Volumn 29, Issue 6, 2009, Pages 636-642

  Sherrard, Donald J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

bisphosphonates; fractures; Osteodystrophy; osteoporosis; steroids

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; COLECALCIFEROL; ETIDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; STEROID; VITAMIN D;

AGING; ARTICLE; BONE DENSITY; BONE NECROSIS; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE CLEARANCE; DIABETES MELLITUS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HIP FRACTURE; HUMAN; JAW OSTEONECROSIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALNUTRITION; OSTEOPENIA; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SENILE OSTEOPOROSIS; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; WEIGHT BEARING;

AGED; AGING; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; EXERCISE THERAPY; FEMALE; HIP FRACTURES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 71549144420     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2009.07.007     Document Type: Article

References (22)

1. Sherrard D.J. Aluminum-much ado about something. N Engl J Med 324 (1991) 558-559
2. Johnson C., Graham B., Kings F., and Curtis B. Roentgenographic manifestations of chronic renal disease treated by intermittent hemodialysis. AJR Am J Roentgenol 101 (1967) 915-926
3. Sherrard D.J. Renal osteodystrophy. Semin Nephrol 6 (1986) 56-67
4. Brickman A.S., Sherrard D.J., Jowsey J., et al. 1,25 dihydrocholecalciferol in uremic osteodystrophy. Arch Intern Med 134 (1974) 883-888
5. Antonsen J.E., Sherrard D.J., and Andress D.L. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 53 (1998) 223-227
6. Sherrard D.J. Calcimimetics in action. Kidney Int 53 (1998) 510-511
7. Melton A.L. Hip fractures in the elderly: a world wide projection. Osteoporosis Int 2 (1983) 285-293
8. Alem A., Sherrard D.J., Gillen D.L., et al. Increased risk of hip fractures among patients with end stage renal disease. Kidney Int 58 (2000) 396-399
9. Stehman-Breen C., Sherrard D.J., Alem A., et al. Risk factors of hip fracture among patents with endstage renal disease. Kidney Int 58 (2000) 2200-2205
10. The Physicians Desk Reference. Fosamax 60 (2006) 1949-1956
11. Boutsen Y., Jamart J., and Eiselinckx J.P. Primary prevention of glucocorticoid-induced osteoporosis with intravenous calcium and pamidronate. J Bone Miner Res 16 (2001) 104-112
12. Shane E. Osteoporosis associated with illness and medications. In: Marcus R., Feldman D., and Kelsey J. (Eds). Osteoporosis (1996), Academic Press, San Diego 925-946
13. Melton L.J., Leibson C.T., Aschenbach S.J., et al. Fracture risk in type 2 diabetes: update of a population based study. J Bone Miner Res 23 (2008) 1334-1342
14. Turner C.H., and Robling A.G. Exercise as an anabolic stimulus to bone. Curr Pharm Des 10 (1998) 2629-2641
15. Arnaud S.B., Sherrard D.J., Maloney N., et al. Effects of one week head down tilt bed rest on bone formation and the calcium endocrine system. Aviat Space Environ Med 63 (1992) 14-20
16. Holick M.F. Vitamin D deficiency. N Engl J Med 357 (2007) 266-279
17. Miller P.D., Roux C., Brown S., et al. Safety and efficacy of risedronate in patients with age related renal function impairment as estimated by the Cockcroft and Gault method. A pooled analysis of nine clinical trials. J Bone Miner Res 12 (2005) 2105-2115
18. Toussaint N.G., Elder G.J., and Kerr P.C. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4 (2009) 221-233
19. Woo S.B., Hellstein J.W., and Kalmer J.R. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
20. Perazella M.A., and Markowitz G.S. Bisphosphonate nephrotoxicity. Kidney Int 74 (2008) 1385-1393
21. Black D.M. Effects of continuing or stopping Alendronate after 5 years of treatment. JAMA 296 (2006) 2927-2938
22. Ott S.M. Long term safety of bisphosphonates. J Clin Endocrinol Metab 90 (2005) 1897-1899